PHARMANIAGA BHD

KLSE (MYR): PHARMA (7081)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

0.45

Today's Change

0.00 (0.00%)

Day's Change

0.44 - 0.455

Trading Volume

2,229,300

Financial
Market Cap

Market Cap

649 Million

NOSH

1,441 Million

Latest Quarter

Latest Quarter

31-Mar-2024 [#1]

Announcement Date

27-May-2024

Next Quarter

30-Jun-2024

Est. Ann. Date

11-Aug-2024

Est. Ann. Due Date

29-Aug-2024

QoQ | YoY

178.38% | 868.50%

T4Q Result

Revenue | NP to SH

3,488,986.000 | -54,453.000

RPS | P/RPS

242.08 Cent | 0.19

EPS | P/E | EY

-3.78 Cent | -11.91 | -8.40%

DPS | DY | Payout %

0.00 Cent | 0.00% | 0.00%

NAPS | P/NAPS

-0.19 | 0.00

QoQ | YoY

29.69% | 91.39%

NP Margin | ROE

-1.51% | 0.00%

F.Y. | Ann. Date

31-Mar-2024 | 27-May-2024

Latest Audited Result

Latest Audited Result

31-Dec-2023

Announcement Date

29-Apr-2024

Next Audited Result

31-Dec-2024

Est. Ann. Date

29-Apr-2025

Est. Ann. Due Date

29-Jun-2025

Annual (Unaudited)

Revenue | NP to SH

3,404,481.000 | -77,452.000

RPS | P/RPS

236.22 Cent | 0.19

EPS | P/E | EY

-5.37 Cent | -8.37 | -11.94%

DPS | DY | Payout %

0.00 Cent | 0.00% | 0.00%

NAPS | P/NAPS

-0.20 | 0.00

YoY

87.25%

NP Margin | ROE

-2.23% | 0.00%

F.Y. | Ann. Date

31-Dec-2023 | 29-Feb-2024

Annualized Result

Revenue | NP to SH

3,859,836.000 | 102,584.000

RPS | P/RPS

267.82 Cent | 0.17

EPS | P/E | EY

7.12 Cent | 6.32 | 15.82%

DPS | DY | Payout %

-

NAPS | P/NAPS

-

QoQ | YoY

232.45% | 868.5%

NP Margin | ROE

2.71% | 0.00%

F.Y. | Ann. Date

31-Mar-2024 | 27-May-2024

Business Process

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 1 / 4 25.00% 1 / 8 12.50%
Total Positive Profit Years 2 / 4 50.00% 5 / 8 62.50%
Continuous Quarters Of Positive Profit 1 / 4 25.00% 1 / 8 12.50%
Continuous Quarters Of Profit Growth 2 / 4 50.00% 2 / 8 25.00%
Continuous Quarters Of Adjusted EPS Growth 2 / 4 50.00% 2 / 8 25.00%
Total Dividend Years 0 / 4 0.00% 2 / 8 25.00%
Continuous Quarters Of Dividend 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 0 / 4 0.00% 0 / 8 0.00%
Average ROE 0.00% 0.28%
Average Net Profit Margin -1.66% -9.98%

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Quarters Of Revenue Growth 0 / 5 0.00% 0 / 10 0.00%
Total Positive Profit Years 2 / 5 40.00% 7 / 10 70.00%
Continuous Quarters Of Positive Profit 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Profit Growth 1 / 5 20.00% 1 / 10 10.00%
Continuous Quarters Of Adjusted EPS Growth 1 / 5 20.00% 1 / 10 10.00%
Total Dividend Years 4 / 5 80.00% 9 / 10 90.00%
Continuous Quarters Of Dividend 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Dividend Growth 0 / 5 0.00% 0 / 10 0.00%
Continuous Quarters Of Adjusted Dps Growth 0 / 5 0.00% 0 / 10 0.00%
Average ROE 0.41% 6.29%
Average Net Profit Margin -4.04% -0.57%
Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 3,488,986 3,859,836 3,404,481 2,848,595 3,455,154
NP to SH -54,453 102,584 -77,452 -31,457 -126,869
Dividend 0 0 0 48,015 39,519
Adjusted EPS -3.78 7.12 -5.37 -2.18 -8.80
Adjusted DPS 0.00 0.00 0.00 3.33 2.74

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.

Growth

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue 22.18% 9.60% 9.60% 10.63% 11.59%
NP to Owner 178.38% 868.50% 868.50% 288.39% 129.87%
Dividend 0.00% 0.00% 0.00% 0.00% 0.00%
Adjusted EPS 178.40% 868.80% 868.80% 288.48% 129.88%
Adjusted DPS 0.00% 0.00% 0.00% 0.00% 0.00%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 2.48% 0.98% 22.48% 13.38% 11.71% 35.50% -3.02% -1.47% 19.51%
NP to Owner 29.69% 57.08% -73.10% 232.45% 180.86% 426.11% 87.25% 38.95% -146.21%
Dividend 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Adjusted EPS 29.66% 57.06% -73.18% 232.49% 180.88% 426.21% 87.25% 38.95% -146.21%
Adjusted DPS 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Discussions
6 people like this. Showing 50 of 14,103 comments

nuemeslau

too big to fail

2 months ago

RInvest

Nothing is too big to fail ... just that this is linked to political FD

2 months ago

AmirIffaan

Betul, it's too big to fail

2 months ago

nuemeslau

Our government won't let this company go down one, likely outcome :
1. Pharma turn profitable for a few quarters, bursa then approved their regularization plan and get out of PN17
2. If they can't turn profitable, bursa rejects their regularization plan, then government will have no choice but to bailout pharma by privatizing it

2 months ago

RInvest

Is the quarter result going to be out later?

2 months ago

AmirIffaan

Pharma naik sebelum q1nya keluar. Jadi hijau ?

2 months ago

nuemeslau

go big or go home

2 months ago

Newplayer01

Go go go Pharmaniaga. Please go up gao gao💪🏻💪🏻💪🏻

2 months ago

RInvest

How high ? Keluar PN17 ka?

2 months ago

nuemeslau

ikan masin flipping

1 month ago

babyuser111

terbang

1 month ago

Ron90

insider trading observed ! 😂

1 month ago

Newplayer01

RInvest, they will definitely keluar PN17, Malaysia won’t let Pharma GG. I want the price reach Pandemic level, but don’t don’t MCO la.

1 month ago

Ron90

Price already up 30 % (9 cents) cents..prior to the QR announcement.. clearly information leaked very very early (3 days ahead) to those shark.
If SC/Bursa not siasat and no use la this gahment when dealing with glc company.

1 month ago

RInvest

Newpayer01 - that's exactly what I'm banking on - keluar PN17 - will shoot up .... at least back to 42 cents

1 month ago

AmirIffaan

Come back is real ?

1 month ago

Cipta

yes! The come back is real. But it is Zul.

1 month ago

RInvest

Good come back? Or Bleh only ...

1 month ago

AmirIffaan

Boleh boleh only saya rasa

1 month ago

Michael Kwok

Ong or no ong.will see in 3-5 trading days.
11/6/24 5.24pm

1 month ago

AmirIffaan

Pecah 40 sen baru Ong 😀

1 month ago

AmirIffaan

Pharma sedang fix masalahnya. https://theedgemalaysia.com/node/714064

1 month ago

AlanTew

this is in fact a high potential stock with a very cheap price. If they change the way of managing (and i can see they are doing now) the company like rest of the pharma ind. Pharma price would be at least above rm3.

1 month ago

AmirIffaan

Jadi, tukar pihak pengurusan? 😁

4 weeks ago

Ron90

can accumulate at this level..

2 weeks ago

RInvest

Some action - news?

2 weeks ago

Ron90

this is not a problematic company, its the gahmen yg forced them to hsndle covid vaccine till over supply..when kovid gone..stuck with oversupply dose.. ask Kj ler. now, gahmen hv silently help to fix the problem. Nx Qr will be more prolific..high probability Revenue over 1b. Current price consider low already..good to enter. Down side minimum..upper side. 50 cents 👍

2 weeks ago

Ron90

might get release from PN17 status, anytime soon :-)

2 weeks ago

RInvest

Looking good ...

2 weeks ago

newbie9893

Phama resistance breakout...heading to 0.5

2 weeks ago

AlanTew

Look at other pharma players, their shares are all above RM2. This is the reason I said Pharmaniaga is underrated and it should be priced about RM4 if they are managing it well like others.

2 weeks ago

Ron90

current management good already, managed to submit their restructuring plan early this year, you compare with other PN17 company, take yearssss to submit even the first plan. % months olready, and Bursa should give the approval anytime soon. I would expect this month.. BTW, Next QR should touch 1 billion revenue. Imagine how many people in Indonesia?? They just open news branch in Feb 2024.. next QR will be full 3 months (mac - June) sales.

" In the Indonesia segment, the revenue growth was due to the surge in demand for products of existing principals and additional sales generated from the opening of two
new branches in February 2024."

2 weeks ago

newbie9893

pharma..uptread mode..buy now to be rewarded soon

1 week ago

AlanTew

it will keep moving up steadily until the next QR released, if the report is good it will goes up further above RM1, and how high it could goes higher depends on the consistency of their financial performance as well as dividend given.

1 week ago

AlanTew

Good morning guys, would like to congrats those who bought pharma at 30+- cents, the huge profit is awaiting us.

1 week ago

AlanTew

for those who still have bullets may consider to get a train ticket asap as the gap of the stock price as of now to it supposed to be is big. big potential stock for mid term good profit investment.

1 week ago

AmirIffaan

Ada LTAT, kutip sahaja semasa Pharma adalah murah

1 week ago

Ron90

either regulation plan approved by Bursa or 1 billion revenue will makes this counter fly towards at least 50 cents! .

1 week ago

Ron90

didnt seem to stop... up up .. :-)

1 week ago

AlanTew

It will be keep going up for sure as the company is in good shape now and keep improving from varies aspects. Bear in mind pharma is essential and is must + Pharmaniaga is the sole appointed supplier of nation.

1 week ago

Ron90

anticipating Bursa announcement about its regulation plan. Once out, should prepare how to act ..

1 week ago

Jojo3826

Harap lepas 45sen today

6 days ago

AmirIffaan

Sudah habis cuci la, notinside751 dan Pharma sedang naik sekarangan

6 days ago

Ron90

patient.. next QR will produce revenue above 1 Billion.. and out from PN17 status!. Grab it while still below 50 cents.. end of year above 60 cents

5 days ago

notinside751

Regularisation approved?

5 days ago

DrLimKH

Wave B just completed

3 days ago

DrLimKH

Ba=Bc......

3 days ago

soon9913

And the catalyst that is likely to change the fortunes of the company — a proposed renounceable rights issue with warrants as a sweetener to shareholders that is slated to raise up to RM354.6 million; and, more importantly, a proposed private placement to a third-party investor or investors that could raise gross proceeds of up to RM300 million — could happen soon. Both the rights issue and placement are part of a regularisation plan to get Pharmaniaga out of PN17 classification, but are likely to have a far-reaching impact if management’s plans pan out.

2 days ago

soon9913

Don't all in, get ready some money to subscribe the right issue

2 days ago

Ron90

got nothing to do with Biden drops from presidential race .. people over here still need pills and treatment. Pelaung to top up😅

1 day ago

Post a Comment